Nektar Therapeutics
NKTR- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0000906709
In the last 90 days, Nektar Therapeutics insiders filed 0 open-market purchases and 2 sales; 242 institutions reported holding it in 13F filings for Q3 2026, worth $2.17B in total; no superinvestor holds it.
Key figures
- Market capClose on Nov 19, 2026
- $1.11B
- Insider buysOpen market, last 90 days
- 0
- Insider sellsLast 90 days, $22.3K in total
- 2
- 13F holdersQ3 2026, +5 vs. previous quarter
- 242
- 13F valueReported value at the end of Q3 2026
- $2.17B
- Superinvestors holdingAt the end of Q3 2026
- 0
Price chart
Financials
See financial statementsFrom SEC filings, in USD.
- Revenue, FY2025
- $55.2M
- −43.9% year over year
- Net income, FY2025
- -$164.1M
- No comparable prior period
- Free cash flow, FY2025
- -$208.7M
- No comparable prior period
- Revenue, Q3 FY2026
- $9.39M
- −20.4% year over year
Revenue flow, FY2025
Green is profit; orange is costs, expenses and taxes. Percentages are shares of revenue.
Net loss for FY2025: $164.1M (297.1% of revenue).
Short interest
See short dataFrom FINRA, settlement date Oct 30, 2026.
- Short interest
- 6.77M
- Shares sold short
- Change
- −231.7K
- −3.3% vs. previous
- Days to cover
- 10.26
- At average daily volume
Superinvestors holding NKTR, Q3 2026
Go to the superinvestors tabNo superinvestor reported holding NKTR at the end of Q3 2026.
Latest insider trades
See all insider tradesOpen-market purchases and sales by Nektar Therapeutics insiders from Form 4, newest first.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Nov 19, 2026 (view filing)6:50 PM ET | Nov 17 | 2 days | Robin Howard WPresident & CEO | SSale | −429 | $35.85 | −$15.4K | −0.8%54.2K after | |
| Nov 19, 2026 (view filing)6:50 PM ET | Nov 17 | 2 days | Zalevsky JonathanChief R&D Officer | SSale | −192 | $35.85 | −$6.88K | −2.0%9.38K after | |
| Aug 20, 2026 (view filing)7:05 PM ET | Aug 18 | 2 days | Zalevsky JonathanChief R&D Officer | SSale | −186 | $71.98 | −$13.4K | −1.9%9.57K after | |
| Aug 20, 2026 (view filing)7:03 PM ET | Aug 18 | 2 days | Robin Howard WPresident & CEO | SSale | −418 | $71.98 | −$30.1K | −0.8%54.6K after | |
| Jul 2, 2026 (view filing)7:06 PM ET | Jun 30 | 2 days | Zalevsky JonathanChief R&D Officer | SSale | −5.68K | $70.00 | −$397.7K | −36.8%9.76K after | 10b5-1 |
| Jun 18, 2026 (view filing) | Jun 16-17 | 2 days | Robin Howard WPresident & CEO | SSale | −20.0K | $60.75 | −$1.22M | −26.7%55.0K after | 4 lots10b5-1 |
| Jun 17, 2026 (view filing) | Jun 15 | 2 days | Zalevsky JonathanChief R&D Officer | SSale | −5.54K | $60.71 | −$336.2K | −26.4%15.4K after | 10b5-1 |
| May 21, 2026 (view filing) | May 19 | 2 days | Zalevsky JonathanChief R&D Officer | SSale | −199 | $65.51 | −$13.0K | −0.9%21.0K after | |
| May 21, 2026 (view filing) | May 19 | 2 days | Robin Howard WPresident & CEO | SSale | −444 | $65.51 | −$29.1K | −0.6%75.0K after | |
| Feb 20, 2026 (view filing) | Feb 18 | 2 days | Zalevsky JonathanChief R&D Officer | SSale | −180 | $73.00 | −$13.1K | −0.8%21.2K after |
Top 10 13F holders, Q3 2026
See all 242 holdersThe largest institutional positions in Nektar Therapeutics at the end of Q3 2026; share changes are against Q2 2026.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| FMR LLC | 5,121,441 | $310.1M | 0.01% | +53,521+1.1% | Added |
| Two Seas Capital LP | 3,345,978 | $202.6M | 8.07% | +253,744+8.2% | Added |
| BlackRock, Inc. | 2,871,463 | $173.9M | 0.00% | −70,388−2.4% | Reduced |
| BVF Inc | 2,134,007 | $129.2M | 4.25% | −257,068−10.8% | Reduced |
| State Street Corp | 1,772,302 | $107.3M | 0.00% | +862,623+94.8% | Added |
| Vanguard Capital Management LLC | 1,501,608 | $90.9M | 0.00% | +4,759+0.3% | Added |
| Two Sigma Investments, LP | 1,208,270 | $73.2M | 0.05% | +6,266+0.5% | Added |
| Geode Capital Management, LLC | 891,927 | $54.0M | 0.00% | +10,621+1.2% | Added |
| Morgan Stanley | 830,210 | $50.3M | 0.00% | −106,350−11.4% | Reduced |
| Prosight Management, LP | 785,000 | $47.5M | 9.22% | −25,000−3.1% | Reduced |
Holders of 5% or more of NKTR
See all 7 holders and filingsHolders whose latest Schedule 13D or 13G filing reports 5% or more of Nektar Therapeutics.
| Holder | Latest form | Stake | Change | First filed | Latest filing | Filing |
|---|---|---|---|---|---|---|
| FMR LLC | 13G/A | 15.00%4.30M shares | +3.90 ppfrom 11.10% | Feb 8, 20215 filings | May 6, 2026 | SEC |
| Two Seas Capital LP | 13G/A | 9.80%3.35M shares | +0.70 ppfrom 9.10% | Apr 17, 20263 filings | Sep 28, 2026 | SEC |
| BlackRock, Inc. | 13G | 7.80%2.64M shares | +6.20 ppfrom 1.60% | Jul 18, 20252 filings | Jul 29, 2026 | SEC |
| Biotechnology Value Fund L P | 13G/A | 7.10%2.39M shares | −2.70 ppfrom 9.80% | Jul 9, 20253 filings | Aug 14, 2026 | SEC |
| BlackRock, Inc. | 13G/A | 6.70%12.5M shares | – | Oct 22, 20243 filings | Apr 17, 2025 | SEC |